Introduction
Respiratory failure secondary to obstruction of pulmonary airways is the cause of death in more than 90% of people with cystic fibrosis (CF) [1] . Widely used therapy for CF patients includes antibiotics, airway clearance techniques and devices, pancreatic enzymes and nutritional supplements, as well as drugs such as dornase alfa, hypertonic saline, ibuprofen and inhaled bronchodilators [1] . No bronchodilator is currently approved for the treatment of CF, although their use is widespread. Several studies have provided evidence for efficacy of inhaled β2 adrenergic receptor agonists in people with CF, but the evidence is currently insufficient to recommend them for long-term care [2] .
Tiotropium bromide is a once-daily, long-acting anticholinergic bronchodilator with the potential to improve lung function and alleviate symptoms in people with CF. Tiotropium can be delivered via Respimat ® Soft Mist™ Inhaler (SMI), proven to be suitable even in children aged <5 years with a valved holding chamber (VHC), the AeroChamber Plus ® with facemask [3, 4] . In a phase 2 trial investigating two doses (2.5 and 5 µg once daily), tiotropium Respimat ® dose-dependently improved lung function [5] . Based on the available efficacy, safety and pharmacokinetic data on the use of tiotropium in people with CF, the 5 μg dose was chosen for the current phase 3 study.
The objective of this phase 3 study was to determine the efficacy and safety of tiotropium Respimat ® 5 μg versus placebo as add-on to usual maintenance therapy in people with CF. Based on the phase 2 trial results [5] , we hypothesized that treatment with tiotropium for 12 weeks is more effective in improving lung function compared with placebo in people with CF of all ages.
Methods

Phase 3 trial
Study design
This 12-week multinational, multicenter, randomized, placebo-controlled, double-blind, parallelgroup, phase 3 trial compared the efficacy and safety of tiotropium Respimat ® (5 µg, two 2.5 µg puffs 4 once daily) with placebo. An open-label extension (12-60 weeks) assessed long-term safety and electrocardiogram (ECG) effects of tiotropium ( Supplementary Fig. 1 ). Randomization was stratified by age group ( Supplementary Fig. 2 ). The local institutional review board/independent ethics committee granted ethical approval. Written informed consent was obtained from each patient or the patient's legal representative. An external data safety monitoring board committee (associated with Cystic Fibrosis Foundation Therapeutics, Bethesda, Maryland, USA) monitored safety.
Participants
Inclusion and exclusion criteria are listed in full in the supplementary materials. Briefly, stable participants with a clear diagnosis of cystic fibrosis (children 5-11 years, adolescents ≥12 years and adults ≥18 years) were screened for pre-bronchodilator forced expiratory volume in 1 s (FEV 1 ) ≥25%
of predicted values [6, 7] (no upper limit). Children <5 years were included in the safety analyses only.
Each patient was trained on the inhaler device using a placebo Respimat ® (with VHC for patients <5 years). Usual CF maintenance therapy was continued during the study.
Endpoints
Co-primary endpoints were change from baseline (randomization) to 12 weeks in percent-predicted FEV 1 area under the curve from 0 to 4 h (AUC 0-4h ), chosen as a more accurate representation of the response over time than individual time points, and trough FEV 1 percent-predicted. Secondary pulmonary endpoints were changes from baseline to 12 weeks in forced vital capacity (FVC) AUC 0-4h percent-predicted, trough FVC percent-predicted and forced expiratory flow (FEF) between 25% and 75% of FVC (FEF 25−75 ) percent-predicted.
Additional secondary endpoints were change from baseline to 12 weeks in the revised CF questionnaire (CFQ-R) [8] and the proportion of patients with ≥1 pulmonary exacerbation during the double-blind treatment period as assessed by the Respiratory and Systemic Symptoms Questionnaire (RSSQ) method [9, 10] after 12 weeks (further details in supplementary methods). 5 Safety and tolerability assessment was based on adverse event (AE) incidence, changes in vital signs, physical examination, clinical laboratory tests and ECG substudy results (supplementary methods).
Assessments
Pulmonary function tests (PFTs), FEV 1 and FVC were conducted according to American Thoracic Society/European Respiratory Society criteria [11] at screening visit (1 week before start of treatment); at weeks 1, 4 and 12 (double-blind part); at weeks 24-60 (open-label part); and at the endof-treatment visit. At weeks 1 and 12 (day 85), PFTs were performed pre-dose (-10 min prior to study drug inhalation), at 30 min, and at 1, 2, 3 and 4 h after inhalation of study drug. At week 4 and weeks 24-60, PFTs were only carried out 30 min (±10 min) prior to drug administration. At the end of treatment, a single PFT was performed.
Statistical analyses
To assess efficacy, ≥360 patients were required to be randomized to tiotropium 5 µg or placebo in a 2:1 ratio. Primary analyses were performed in all treated patients who had ≥1 baseline PFT measurement and ≥1 post-baseline on-treatment PFT measurement. Change from baseline in the coprimary efficacy variables (FEV 1 AUC 0-4h and trough FEV 1 ) and all secondary endpoints was analyzed using a restricted maximum likelihood-based mixed-effect model with repeated measures (MMRM). The MMRM included "treatment," "visit," "treatment-by-visit interaction" and "age group" (≤11, ≥12 years) as fixed categorical effects, and "baseline measurement" and "baseline-byvisit interaction" as continuous covariates. Unstructured (co)variance was used to model the withinpatient errors. Superiority of treatment with tiotropium over placebo was tested at the α=0.025 (onesided) level.
Sensitivity analyses to confirm the robustness of the primary results included MMRM analysis in liters, MMRM analysis with observed cases instead of imputed values (further details in the 6 supplementary material) and analysis of covariance (ANCOVA). For the co-primary endpoints, prespecified subgroup analyses by age (≤11, ≥12 years) and concomitant long-acting β 2 agonist (LABA) use at baseline (yes/no) were performed. Treatment-by-subgroup interactions with interaction test pvalues <0.1 were considered significant. For the analysis of the proportion of patients with ≥1 pulmonary exacerbation during the double-blind period (RSSQ), logistic regression with "treatment," "age group," "baseline weight" and "baseline predicted FEV 1 " as covariates was used. For the CFQ-R, descriptive statistics were provided.
Safety endpoints were summarized descriptively. Blinding and randomization, sample size and handling of missing data are detailed in the supplementary methods. Analyses were implemented using Statistical Analysis System software version 9.2 (SAS Institute Inc., Cary, North Carolina, USA).
Pre-specified pooling of phase 2 and 3 trials
The randomized, double-blind, 12-week clinical phase 2 [5] and 3 trials had identical design, outcome measures, and inclusion and exclusion criteria to enable pooling. The primary analysis model for PFTs for the pooled analysis mirrored the analysis of the individual trials, with the addition of trial as a factor in the models. In addition to those pre-specified in the phase 2 and 3 trials, the following subgroups were pre-specified for the pooled analysis of the co-primary endpoints: baseline inhaled antibiotic use, asthma, screening lung function (<80%/≥80% predicted FEV 1 ) and sex. Safety and tolerability assessment was based on AE incidence in the pooled population. 7 
Results
Phase 3 trial
The trial, conducted at 99 sites (20 countries) ran from November 11, 2010, to March 7, 2012. Patient disposition is summarized in Supplementary Fig. 3 . In total, 464 people with CF were randomized and 463 received treatment (tiotropium, 308; placebo, 155). Mean (standard deviation; SD) age was 19.8 (12.5) years, ranging from 5 months (0.4 years) to 70.5 years. A total of 441 patients (95% of those treated) completed the double-blind treatment period and continued into the open-label active treatment phase. Overall, the demographic profile was balanced between the treatment groups and baseline characteristics were as expected for a study population with CF ( Table 1) . 8 
Co-primary efficacy endpoints
There was no statistical difference between tiotropium and placebo for either co-primary efficacy endpoint ( Fig. 1A ; tables 2 and 3; change from baseline difference of tiotropium versus placebo in percent-predicted FEV 1 AUC 0-4h : 1.64%; 95% confidence interval [CI] -0.27 to 3.55; p=0.092, and percent-predicted trough FEV 1 : 1.40%; 95% CI -0.50 to 3.30; p=0.15).
The results of the primary analyses were supported by the results of sensitivity analyses based on analyses in liters (tables 2 and 3), ANCOVAs and observed case analyses (Supplementary Table 1 ).
Assessment by age showed a greater difference in FEV 1 AUC 0-4h (percent-predicted) between tiotropium and placebo in patients aged ≥12 years (2.58%, 95% CI 0.50 to 4.65) than ≤11 years (-0.63%; 95% CI -4.58 to 3.32 ). An improvement in lung function with placebo was observed, driven by results from patients aged ≤11 years (tables 2 and 3).
The difference between tiotropium and placebo for the change in percent-predicted FEV 1 AUC 0-4h was greater for patients taking concomitant LABA at baseline (3.40%, 95% CI 1.50 to 5.30) than not (1.80%, 95% CI 0.38 to 3.21). This was also true for patients with a screening FEV 1 of <80% (3.00%, 95% CI 1.40 to 4.60) compared with those patients with a screening FEV 1 of ≥80% (1.11%, 95% CI -0.52 to 2.74). 10 
Other lung function measures
Secondary spirometry endpoints results followed those for co-primary endpoints: tiotropium and placebo differences in FVC AUC 0−4h change from baseline in percent-predicted, 1.09% (95% CI -0.68 to 2.86; p=0.23), trough FVC, 1.20% (95% CI -0.62 to 3.02; p=0.19) and FEF 25−75 , 0.86% (95% CI -2.59 to 4.32; p=0.62). 
Pulmonary exacerbations and quality of life
Safety
During the double-blind period of this study, AEs were reported at a similar frequency in the tiotropium and placebo groups (tiotropium, 65%; placebo, 68%; Table 4 ). The most frequently reported AEs were in the system organ classes (SOCs) of infections and infestations and respiratory, thoracic and mediastinal disorders, with cough being the most frequently reported AE (tiotropium, 18%; placebo, 13%; Supplementary Table 2 ). Drug-related AEs were balanced between treatment groups. Serious AEs (SAEs) were reported at a higher frequency in the tiotropium group (tiotropium, 12%, placebo, 8%). The treatment difference was driven partly by a greater proportion of AEs in the infections and infestations SOC (in particular pneumonia) and by a slightly higher percentage of individuals with pulmonary exacerbation in the tiotropium group.
No unexpected findings were noted in the results from the open-label treatment period, the entire main period and the ECG study ( Supplementary Table 3 ). 
Pre-specified pooled phase 2 and phase 3 study results
Of the 808 patients randomized to tiotropium 5 µg or placebo in the two trials, 807 were included in the treated set of the pooled analysis, with an approximate 1:2 ratio of patients aged ≤11 years and patients aged ≥12 years (546 patients, 68%). The characteristics of people with CF were comparable between the two trials (including mean [SD] age 20.3 [12.1] years, range 0.4-69.7) and well balanced between treatment groups (Table 1) .
A difference of 2.62% (95% CI 1.34 to 3.90) in favor of tiotropium was observed in the change from baseline in percent-predicted FEV 1 AUC 0-4h and of 1.85% (95% CI 0.53 to 3.18) in percent-predicted trough FEV 1 (Fig. 1B, tables 2 and 3 ). There was also a difference in favor of tiotropium for the adjusted mean changes from baseline to week 12 in FEV 1 AUC 0-4h in liters (0.085 L; 95% CI 0.050 to 0.121) and in trough FEV 1 (0.064 L; 95% CI 0.028 to 0.100). There were also positive differences in FEV 1 AUC 0-4h (adjusted means between 1.43-4.65% predicted) in favor of tiotropium 5 µg across all subgroups assessed (age, sex, screening lung function, baseline use of LABA, inhaled antibiotics and asthma at baseline), although children aged ≤11 years, patients with a FEV 1 ≥80% and those not taking LABA at baseline seem to derive less benefit from tiotropium treatment ( Supplementary Fig.   4 ). The unadjusted mean changes from baseline to week 12 for percent predicted FEV 1 Table 6 ). In the pooled analysis, the safety and tolerability of tiotropium were comparable overall with placebo (supplementary results).
Discussion
In the phase 3 trial, tiotropium was associated with small improvements in spirometry endpoints, but statistical significance versus placebo was not reached. A pre-specified pooling of the phase 2 and 3 trials was performed to enhance the precision of estimates and to evaluate the effects in various subgroups of interest; both co-primary endpoints demonstrated improvements in lung function with tiotropium versus placebo. No effect was seen in pulmonary exacerbation rates or respiratory symptoms quantified by CFQ-R.
The difference in outcomes from the phase 2 [5] and 3 trials were largely driven by the ≤11-year age group, though the reasons for this are not clear. The high frequency of patients with >80% FEV 1 predicted at screening in this age group may have reduced the chances of improvements in lung function. However, in the phase 3 trial, patients ≤11years in the placebo group showed an improvement in percent-predicted FEV 1 AUC 0-4h over time, which suggests a learning effect during the trial among the younger patients, who were less skilled in performing spirometry. In a recent study of inhaled mannitol, a sustained, significant (p<0.001) improvement in FEV 1 was seen in the control group [12] , but the improvement was not significant in another similarly designed study (p=0.059) in similar populations [13] . Interestingly, in the pooled analysis, significant improvements in the mannitol versus control group in FEV 1 occurred in patients aged ≥18 years old but not in younger 20 participants [14] . Furthermore, and similar to the current study, improvements in percent-predicted FEV 1 were observed in the placebo group in the 6-17-year age group [14] , raising the question of whether more intense pulmonary function testing should be done as a run-in phase in children and adolescents (≤18 years) with CF.
The trial included people with CF of all ages (5 months to 70.5 years) and disease severities; it can therefore be considered of clinical relevance. Overall, the broad inclusion criteria for the tiotropium trials in CF facilitated patient recruitment but may have limited the chance of showing efficacy in improving pulmonary function and symptoms. Subgroup analyses suggest that adolescents and adults with CF, those with lower FEV 1 and those taking concomitant LABA were more likely to achieve greater benefit from long-term treatment with tiotropium.
People with CF use complex and intense medication regimens. In this study, tiotropium was tested on top of usual CF maintenance therapy, including bronchodilators such as short-acting β 2 agonists, LABAs and LABA/inhaled corticosteroid combinations, antibiotics, inhaled antibiotics and mucolytics. The magnitude of improvement in pulmonary function in percent-predicted FEV 1 AUC 0-4h observed with tiotropium in people with CF (pooled phase 2/3: 2.62%) was relatively small. It is difficult to compare results with those published in the literature since results are presented in terms of relative rather than absolute differences and sometimes with absolute changes in lung volume data rather than percent-predicted data. In two recent identical trials of mannitol in CF in which FEV 1 was expressed in the same way as in our trial (difference versus placebo in percent-predicted FEV 1 was 2.4%, 95% CI 0.9 to 3.9 in one trial [12] and 1.9%, 95% CI -0.02 to 3.8 in the other), changes were similar in magnitude to those demonstrated for tiotropium [13] . Treatment differences must also be considered in light of the study design and short duration of the trials. Patients were already on usual standard of care maintenance therapy and no upper limit of percent-predicted FEV 1 at baseline was set as a criterion for study entry, limiting the room for improvement.
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The numerical, but not statistically significant, increase in infections reported as AEs seen in the phase 3 study was not observed in the phase 2 study; in the pooled analysis, incidence of all AEs in the SOC infections favored placebo, whereas SAEs favored tiotropium. Collectively, safety and tolerability were comparable between tiotropium and placebo.
Conclusion
Efficacy, based on lung function and RSSQ results, of inhaled tiotropium delivered by the Respimat ® SMI in people with CF as add-on to usual CF maintenance therapy was not established in this phase 3 trial. In the pooled phase 2 and 3 results, the improvements in lung function with tiotropium were not accompanied by clinical effects on the frequency of pulmonary exacerbations or quality of life.
Subgroup analyses using pooled phase 2 and 3 results suggest that some individuals with CF may derive clinical benefit from tiotropium. Tiotropium Respimat ® 5 µg was well tolerated in people with CF and the overall safety profile was consistent with that of tiotropium in chronic obstructive pulmonary disease.
